Medicines access index comes under fire
This article was originally published in Scrip
A new report analysing pharmaceutical companies' contribution to improving access to medicines has been attacked by Pfizerand Health Action International (HAI) for failing to paint a true picture of the situation. It was, however, given a cautious welcome by a group of financial institutions.
You may also be interested in...
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.